Navigation Links
TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today promising results of its phase I clinical trials demonstrating the safety and pharmacokinetic profile of its ViaDerm-hPTH (1-34) product for the treatment of osteoporosis.

A seven day, repeated dose application, parallel group study was conducted on 48 healthy, elderly, post-menopausal women. The study was designed to evaluate the safety and tolerability of ascending multiple doses of hPTH (1-34) patches and to compare the pharmacokinetic profiles of the transdermally delivered doses of hPTH (1-34) with that of FORTEO(R) administered subcutaneously.

Transdermal hPTH (1-34) was delivered using TransPharma's fully integrated product, which is comprised of a proprietary pocket-sized device and 1 cm(2) dry hPTH (1-34) patch with demonstrated room-temperature stability.

Once-daily transdermal delivery of all doses tested in this trial demonstrated a safety profile similar to the one observed in the FORTEO(R) subcutaneous injection. All safety parameters (including calcium and phosphorous) of the different transdermal doses were within the normal range. Furthermore, all ViaDerm-hPTH (1-34) doses were very well tolerated by participants.

Pharmacokinetic profiles of hPTH (1-34) in the first and seventh day were similar, showing no accumulation of hPTH (1-34) levels and no deterioration in hPTH (1-34) systemic levels. These findings demonstrate the ViaDerm-hPTH (1-34) product's ability to provide reproducible drug levels resulting in excellent inter- and intra-participant variability.

Transdermally delivered hPTH (1-34) of all doses showed desirable peak profiles with relative bioavailability of approximately 40%. This bioavailability is amo
'"/>




Page: 1 2 3

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
7. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
8. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
9. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
10. Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
(Date:9/1/2015)... Sept. 1, 2015  AccuTec Blades, Inc. today announced ... Blades division.  EPC announced in May 2015 its intent ... Verona, Virginia and Obregon, Mexico ... sale process. Rick Gagliano , ... Blades said, "Our new name, AccuTec Blades, reflects the ...
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... DALLAS , Sept. 1, 2015 UT ... and distinguished faculty members joined U.S. Representatives ... in a roundtable discussion on the 21 st ... biomedical research currently being considered by the ... faculty – including National Academy of Sciences members, department ...
Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5
... Conn., May 15, 2012 /PRNewswire-iReach/ -- Global ... important Cambridge Healthtech Institute conferences: IMVACS – ... August 13 – 15, Cambridge, MA - The ... under one heading: the Seventh Annual Novel Vaccines, Design ...
... Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, ... results for the three months ended March 31, 2012 ... delighted with recent developments that have strengthened and advanced ... David Dodd. "Our Phase 1/2 therapeutic vaccine trial continues ...
Cached Medicine Technology:Attendees Save up to $350 on CHI Conferences This Summer by Registering Through Global Information 2GeoVax Labs Reports 2012 First Quarter Financial Results 2GeoVax Labs Reports 2012 First Quarter Financial Results 3GeoVax Labs Reports 2012 First Quarter Financial Results 4GeoVax Labs Reports 2012 First Quarter Financial Results 5GeoVax Labs Reports 2012 First Quarter Financial Results 6
(Date:9/1/2015)... ... ... September is National Prostate Cancer Awareness Month and Florida Hospital Zephyrhills wants to ... the United States. , Prostate cancer is to men what breast cancer is to ... men. One new case occurs every 2.3 minutes and a man dies from prostate ...
(Date:9/1/2015)... ... , ... According to a study published August 25th in the ... a three year study about weight loss and diabetes were far more likely to ... surgery at the onset of the trial. In fact, the participants in the trial ...
(Date:9/1/2015)... ... 2015 , ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive session ... Compass® has taken place at Kingsborough Community College in Brooklyn in each of the ... for Calvary, and two junior counselors who were campers themselves just a few years ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... of the American Society for Dermatologic Surgery, according to a new survey that ... Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in Houston, TX ... , an innovative vaginal health laser procedure that prevents and resolves dryness in ... atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful intercourse and ...
Breaking Medicine News(10 mins):Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3
... University School of Medicine (BUSM) have discovered new details ... team connected pharmacological properties of the Novartis Pharma AG ... first time after investigating adverse reactions suffered by patients ... osteoporosis. These findings appear online in the Journal ...
... executed a license agreement with The Incubation Factory, St. Louis, ... is pending. The tonometer was developed by a ... Robert Fechtner, MD, director of the glaucoma division at UMDNJ. ... the research team. "We are excited that this ...
... HealthDay Reporter , MONDAY, May 16 (HealthDay News) -- ... "bad" cholesterol levels, and may in fact prompt a very modest ... The finding comes from a six-month examination of the impact ... healthy people in England. , , "The issue is that there ...
... Elsevier, the world-leading publisher of scientific, technical ... launch of Mosby,s Textbook of Dental Nursing. Written ... Assessment Centre for Dental Nurses, Eastman Dental Institute ... of Oral Medicine, Pathology and Microbiology, University of ...
... , WORCESTER, Mass. A new book edited by ... Brook University School of Medicine provides a comprehensive look ... at the leading cause of death---heart disease. "Regenerating the ... is edited by Glenn Gaudette, associate professor of biomedical ...
... institutionalized Romanian children have found that the length of ... correlates with lower IQ and behavioral problems. A ... and Tulane University, shows that early adversity even affects ... as telomeres, and hastening how quickly their cells "age." ...
Cached Medicine News:Health News:NJIT and UMDNJ license personal tonometer technology for innovative glaucoma testing 2Health News:Selenium Supplements Might Give Modest Benefit Against Cholesterol 2Health News:Selenium Supplements Might Give Modest Benefit Against Cholesterol 3Health News:New book explores stem cell therapies for heart disease 2Health News:Deprivation and neglect found to age children's chromosomes 2Health News:Deprivation and neglect found to age children's chromosomes 3
Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Medicine Products: